Sex-specific aspects of tumor therapy

  • Kerstin Borgmann
  • Ekkehard Dikomey
  • Cordula Petersen
  • Petra Feyer
  • Ulrike Hoeller


There is increasing evidence that sex-specific differences in toxicity profiles and outcome after radiotherapy are accumulating in medical oncology, and that treatment strategies may require some modification. Furthermore, sex-specific differences in the sensitivity to genotoxic and therapeutical agents are also of general concern for risk estimation. This review is focussed on the specific influence of sex on these endpoints covering both a clinical and a biological point of view. In this paper, the literature was systematically reviewed with respect to sex-specific differences in tumor and normal tissue sensitivity after exposure to ionizing radiation, as well as to the relevant underlying molecular and cellular mechanisms. Although a number of data on sex-specific differences are available and remarkable differences on clinical, molecular, and cellular levels have been reported, a firm conclusion on any existing sex-specific differences is not yet possible. Future studies are required and should be focussed on this aspect of individual radiosensitivity.


  1. Alexiou C, Onyeaka CV, Beggs D, Akar R, Beggs L, Salama FD, Duffy JP, Morgan WE (2002) Do women live longer following lung resection for carcinoma? Eur J Cardiothorac Surg 21:19–25CrossRefGoogle Scholar
  2. Amador-Noguez D, Zimmerman J, Venable S, Darlington G (2005) Gender-specific alterations in gene expression and loss of liver sexual dimorphism in the long-lived Ames dwarf mice. Biochem Biophys Res Commun 332:1086–1100CrossRefGoogle Scholar
  3. Batevik R, Grong K, Segadal L, Stangeland L (2005) The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer 47:73–81CrossRefGoogle Scholar
  4. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W, MacDonald D, Stitt L, Cairncross JG (1999) Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45:23–29Google Scholar
  5. Baumann M, Krause M, Dikomey E, Dittmann K, Dorr W, Kasten-Pisula U, Rodemann HP (2007) EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83:238–248CrossRefGoogle Scholar
  6. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081–8092CrossRefGoogle Scholar
  7. Besplug J, Burke P, Ponton A, Filkowski J, Titov V, Kovalchuk I, Kovalchuk O (2005) Sex and tissue-specific differences in low-dose radiation-induced oncogenic signalling. Int J Radiat Biol 81:157–168CrossRefGoogle Scholar
  8. Bhatia S, Paulino AC, Buatti JM, Mayr NA, Wen BC (2002) Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 54:818–823Google Scholar
  9. Bradley JD, HopeA El, Naqa I, Apte A, Lindsay PE, Bosch W, Matthews J, Sause W, Graham MV, Deasy JO (2007) A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys 69:985–992Google Scholar
  10. Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E (2007) Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol 33:763–768Google Scholar
  11. Carere A, Antoccia A, Cimini D, Crebelli R, Degrassi F, Leopardi P, Marcon F, Sgura A, Tanzarella C, Zijno A (1999) Analysis of chromosome loss and non-disjunction in cytokinesis-blocked lymphocytes of 24 male subjects. Mutagenesis 14:491–496CrossRefGoogle Scholar
  12. Cassie S, Koturbash I, Hudson D, Baker M, Ilnytskyy Y, Rodriguez-Juarez R, Weber E, Kovalchuk O (2006) Novel retinoblastoma binding protein RBBP9 modulates sex-specific radiation responses in vivo. Carcinogenesis 27:465–474CrossRefGoogle Scholar
  13. Chansky K, Benedetti J, Macdonald JS (2005) Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 103:165–171CrossRefGoogle Scholar
  14. Chatkin JM, Abreu CM, Fritscher CC, Wagner MB, Pinto JA (2004) Is there a gender difference in non-small cell lung cancer survival? Gend Med 1:41–47CrossRefGoogle Scholar
  15. Claus EB, Black PM (2006) Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer 106:358–363CrossRefGoogle Scholar
  16. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW (2000) Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European intergroup cooperative Ewing’s sarcoma study group. J Clin Oncol 18:108–114Google Scholar
  17. D’Amico TA, Aloia TA, Moore MB, Herndon JE 2nd, Brooks KR, Lau CL, Harpole DH Jr (2000) Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg 69:882–886CrossRefGoogle Scholar
  18. Davis M (2005) Gender differences in p-glycoprotein: drug toxicity and response. J Clin Oncol 23:6439–6440CrossRefGoogle Scholar
  19. de Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, van den Bent MJ, Planting AS, Graveland WJ, Stoter G, Verweij J (2003) Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88:1199–1206CrossRefGoogle Scholar
  20. Diaz-Gonzalez JA, Calvo FA, Cortes J, Garcia-Sabrido JL, Gomez-Espi M, Del Valle E, Munoz-Jimenez F, Alvarez E (2006) Prognostic factors for disease-free survival in patients with T3–4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. Int J Radiat Oncol Biol Phys 64:122–128Google Scholar
  21. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD (1995) Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36:473–476CrossRefGoogle Scholar
  22. Ferguson MK, Wang J, Hoffman PC, Haraf DJ, Olak J, Masters GA, Vokes EE (2000) Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg 69:45–49 discussion 249–50CrossRefGoogle Scholar
  23. Fernandes OJ, Almgren SO, Thaning L, Filbey D, Helsing M, Karlsson M, Magnusson A, Souza D (2003) Prognostic factors for the survival of surgically treated patients for non-small cell lung cancer. Acta Oncol 42:38–41CrossRefGoogle Scholar
  24. Fietkau R, Rodel C, Hohenberger W, Raab R, Hess C, Liersch T, Becker H, Wittekind C, Hutter M, Hager E, Karstens J, Ewald H, Christen N, Jagoditsch M, Martus P, Sauer R (2007) Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys 67:008–019Google Scholar
  25. Foegle J, Hedelin G, Lebitasy MP, Purohit A, Velten M, Quoix E (2007) Specific features of non-small cell lung cancer in women: a retrospective study of 1,738 cases diagnosed in Bas-Rhin between 1982 and 1997. J Thorac Oncol 2:66–74CrossRefGoogle Scholar
  26. Fu XL, Zhu XZ, Shi DR, Xiu LZ, Wang LJ, Zhao S, Qian H, Lu HF, Xiang YB, Jiang GL (1999) Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 23:143–152CrossRefGoogle Scholar
  27. Fu JB, Kau TY, Severson RK, Kalemkerian GP (2005) Lung cancer in women: analysis of the national surveillance, epidemiology, and end results database. Chest 127:68–77CrossRefGoogle Scholar
  28. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF (2004) Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44:499–523CrossRefGoogle Scholar
  29. Goldberg SL, Chiang L, Selina N, Hamarman S (2004) Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/secondary prophylaxis strategies. Support Care Cancer 12:526–530CrossRefGoogle Scholar
  30. Govindarajan A, Coburn NG, Kiss A, Rabeneck L, Smith AJ, Law CH (2006) Population-based assessment of the surgical management of locally advanced colorectal cancer. J Natl Cancer Inst 98:474–481Google Scholar
  31. Goyal LK, Suh JH, Mohan DS, Prayson RA, Lee J, Barnett GH (2000) Local control and overall survival in atypical meningioma: a retrospective study. Int J Radiat Oncol Biol Phys 46:7–61CrossRefGoogle Scholar
  32. Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB (2000) Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish society for head and neck oncology. Radiother Oncol 55:21–29CrossRefGoogle Scholar
  33. Gross R, Hirschmann WD (1976) Clinical problems of optimum bioavailability, in particular in cytostatic therapy (author’s transl). Arzneimittelforschung 26:130–135Google Scholar
  34. Gusella M, Crepaldi G, Barile C, Bononi A, Menon D, Toso S, Scapoli D, Stievano L, Ferrazzi E, Grigoletto F, Ferrari M, Padrini R (2006) Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. Ann Oncol 17:1656–1660CrossRefGoogle Scholar
  35. Gutierrez JC, Perez EA, Franceschi D, Moffat FL Jr, Livingstone AS, Koniaris LG (2007) Outcomes for soft-tissue sarcoma in 8,249 cases from a large state cancer registry. J Surg Res 141:05–14CrossRefGoogle Scholar
  36. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V (2000) Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82:1013–1016CrossRefGoogle Scholar
  37. Hando JC, Nath J, Tucker JD (1994) Sex chromosomes, micronuclei and aging in women. Chromosoma 103:186–192CrossRefGoogle Scholar
  38. Hannisdal K, Boysen M, Evensen JF (2003) Different prognostic indices in 310 patients with tonsillar carcinomas. Head Neck 25:23–31CrossRefGoogle Scholar
  39. Harris RC, Chung E, Coffey RJ (2003) EGF receptor ligands. Exp Cell Res 284:2–13CrossRefGoogle Scholar
  40. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 339:506–514CrossRefGoogle Scholar
  41. Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X, Lu Z (2006) Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer 106:1602–1609CrossRefGoogle Scholar
  42. Iarmarcovai G, Bonassi S, Botta A, Baan RA, Orsiere T (2007) Genetic polymorphisms and micronucleus formation: a review of the literature. Mutat Res 658:215–233Google Scholar
  43. Issa JP (2004) CpG island methylator phenotype in cancer. Nat Rev Cancer 4:988–993CrossRefGoogle Scholar
  44. Janne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ, Johnson BE (2004) Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, “Iressa”) on an expanded access study. Lung Cancer 44:221–230CrossRefGoogle Scholar
  45. Johansen LV, Grau C, Overgaard J (2003) Laryngeal carcinoma—multivariate analysis of prognostic factors in 1,252 consecutive patients treated with primary radiotherapy. Acta Oncol 42:71–78CrossRefGoogle Scholar
  46. Joseph LJ, Patwardhan UN, Samuel AM (2004) Frequency of micronuclei in peripheral blood lymphocytes from subjects occupationally exposed to low levels of ionizing radiation. Mutat Res 564:83–88Google Scholar
  47. Keller SM, Vangel MG, Adak S, Wagner H, Schiller JH, Herskovic A, Komaki R, Perry MC, Marks RS, Livingston RB, Johnson DH (2002) The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer 37:303–309CrossRefGoogle Scholar
  48. Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A (2005) Role of hematotoxicity and sex in patients with Hodgkin’s lymphoma: an analysis from the German Hodgkin study group. J Clin Oncol 2:003–011Google Scholar
  49. Kong FM, Hayman JA, Griffith KA, Kalemkerian GP, Arenberg D, Lyons S, Turrisi A, Lichter A, Fraass B, Eisbruch A, Lawrence TS, Ten Haken RK (2006) Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65:1075–1086Google Scholar
  50. Konski A, Desilvio M, Hartsell W, Watkins-Bruner D, Coyne J, Scarantino C, Janjan N (2006) Continuing evidence for poorer treatment outcomes for single male patients: retreatment data from RTOG 97–14. Int J Radiat Oncol Biol Phys 66:229–233Google Scholar
  51. Koturbash I, Baker M, Loree J, Kutanzi K, Hudson D, Pogribny I, Sedelnikova O, Bonner W, Kovalchuk O (2006) Epigenetic dysregulation underlies radiation-induced transgenerational genome instability in vivo. Int J Radiat Oncol Biol Phys 66:327–330Google Scholar
  52. Kovalchuk O, Burke P, Besplug J, Slovack M, Filkowski J, Pogribny I (2004) Methylation changes in muscle and liver tissues of male and female mice exposed to acute and chronic low-dose X-ray-irradiation. Mutat Res 548:75–84Google Scholar
  53. Krakowczyk L, Strzelczyk JK, Adamek B, Zalewska-Ziob M, Arendt J, Poltorak S, Maciejewski B, Wiczkowski A (2008) Methylation of the MGMT and p16 genes in sporadic colorectal carcinoma and corresponding normal colonic mucosa. Med Sci Monit 14:219–225Google Scholar
  54. La JC, Cheng YW, Chiou HL, Wu MF, Chen CY, Lee H (2005) Gender difference in estrogen receptor alpha promoter hypermethylation and its prognostic value in non-small cell lung cancer. Int J Cancer 117:974–980CrossRefGoogle Scholar
  55. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD (2006) Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 24:998–3006Google Scholar
  56. Laskin JJ, Sandler AB (2004) Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 30:1–17CrossRefGoogle Scholar
  57. Lee W, Lockhart AC, Kim RB, Rothenberg ML (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10:104–111CrossRefGoogle Scholar
  58. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefGoogle Scholar
  59. Maffei F, Angelini S, Forti GC, Lodi V, Violante FS, Mattioli S, Hrelia P (2002) Micronuclei frequencies in hospital workers occupationally exposed to low levels of ionizing radiation: influence of smoking status and other factors. Mutagenesis 17:405–409CrossRefGoogle Scholar
  60. Maffei F, Angelini S, Forti GC, Violante FS, Lodi V, Mattioli S, Hrelia P (2004) Spectrum of chromosomal aberrations in peripheral lymphocytes of hospital workers occupationally exposed to low doses of ionizing radiation. Mutat Res 547:91–99Google Scholar
  61. Marcon F, Andreoli C, Rossi S, Verdina A, Galati R, Crebelli R (2003) Assessment of individual sensitivity to ionizing radiation and DNA repair efficiency in a healthy population. Mutat Res 541:1–8Google Scholar
  62. Marosi C (2006) Gender aspects of treatment and drug related toxicity in medical oncology. Wien Med Wochenschr 156:534–540CrossRefGoogle Scholar
  63. Mayer PJ, Lange CS, Bradley MO, Nichols WW (1991) Gender differences in age-related decline in DNA double-strand break damage and repair in lymphocytes. Ann Hum Biol 18:405–415CrossRefGoogle Scholar
  64. Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, Jani AB, Kindler HL, Mundt AJ, Roeske JC, Chmura SJ (2007) Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 70:1431–1437Google Scholar
  65. Mendenhall WM, Morris CG, Amdur RJ, Foote KD, Friedman WA (2003) Radiotherapy alone or after subtotal resection for benign skull base meningiomas. Cancer 98:473–482CrossRefGoogle Scholar
  66. Mendenhall WM, Morris CG, Hinerman RW, Malyapa RS, Amdur RJ (2006) Definitive radiotherapy for nasopharyngeal carcinoma. Am J Clin Oncol 29:22–27Google Scholar
  67. Minami H, Yoshimura M, Miyamoto Y, Matsuoka H, Tsubota N (2000) Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest 118:603–609CrossRefGoogle Scholar
  68. Moore R, Doherty D, Chamberlain R, Khuri F (2004) Sex differences in survival in non-small cell lung cancer patients 1974–1998. Acta Oncol 43:7–64CrossRefGoogle Scholar
  69. Morris ME, Lee HJ, Predko LM (2003) Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol Rev 55:229–240CrossRefGoogle Scholar
  70. Muller WU, Bauch T, Stuben G, Sack H, Streffer C (2001) Radiation sensitivity of lymphocytes from healthy individuals and cancer patients as measured by the comet assay. Radiat Environ Biophys 40:83–89CrossRefGoogle Scholar
  71. Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwar M, Kawasaki N, Konaka C, Kato H (2002) Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 37:161–169CrossRefGoogle Scholar
  72. Okada M, Nishio W, Sakamoto T, Harada H, Uchino K, Tsubota N (2003) Long-term survival and prognostic factors of five-year survivors with complete resection of non-small cell lung carcinoma. J Thorac Cardiovasc Surg 126:58–62Google Scholar
  73. Olive PL, Banath JP, Keyes M (2008) Residual gammaH2AX after irradiation of human lymphocytes and monocytes in vitro and its relation to late effects after prostate brachytherapy. Radiother Oncol 86:336–346CrossRefGoogle Scholar
  74. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyzes including recursive partitioning and amalgamation algorithms in 1, 052 patients. The European lung cancer working party. J Clin Oncol 13:1221–1230Google Scholar
  75. Palazzi M, Tomatis S, Orlandi E, Guzzo M, Sangalli C, Potepan P, Fantini S, Bergamini C, Gavazzi C, Licitra L, Scaramellini G, Cantu G, Olmi P (2008) Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. Int J Radiat Oncol Biol Phys 70:330–337Google Scholar
  76. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311ADSCrossRefGoogle Scholar
  77. Pfannschmidt J, Muley T, Bulzebruck H, Hoffmann H, Dienemann H (2007) Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2,083 patients. Lung Cancer 55:71–77CrossRefGoogle Scholar
  78. Pieters RS, Niemierko A, Fullerton BC, Munzenrider JE (2006) Cauda equina tolerance to high-dose fractionated irradiation. Int J Radiat Oncol Biol Phys 64:251–257Google Scholar
  79. Pogribny I, Raiche J, Slovack M, Kovalchuk O (2004) Dose-dependence, sex- and tissue-specificity, and persistence of radiation-induced genomic DNA methylation changes. Biochem Biophys Res Commun 320:1253–1261CrossRefGoogle Scholar
  80. Port RE, Daniel B, Ding RW, Herrmann R (1991) Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. Oncology 48:277–281CrossRefGoogle Scholar
  81. Radzikowska E, Glaz P, Roszkowski K (2002) Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20,561 cases. Ann Oncol 13:087–093CrossRefGoogle Scholar
  82. Raiche J, Rodriguez-Juarez R, Pogribny I, Kovalchuk O (2004) Sex- and tissue-specific expression of maintenance and de novo DNA methyltransferases upon low dose X-irradiation in mice. Biochem Biophys Res Commun 325:39–47CrossRefGoogle Scholar
  83. Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP (1998) Lung cancer in young patients: analysis of a surveillance, epidemiology, and end results database. J Clin Oncol 16:51–57Google Scholar
  84. Richard F, Muleris M, Dutrillaux B (1994) The frequency of micronuclei with X chromosome increases with age in human females. Mutat Res 316:1–7Google Scholar
  85. Robinson DR, Wu YM, Lin SF (2000) The protein tyrosine kinase family of the human genome. Oncogene 19:5548–5557CrossRefGoogle Scholar
  86. Robnett TJ, Machtay M, Vines EF, McKenna MG, Algazy KM, McKenna WG (2000) Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48:89–94CrossRefGoogle Scholar
  87. Rousseau A, Marquet P (2002) Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 16:253–262CrossRefGoogle Scholar
  88. Schmitz A, Bayer J, Dechamps N, Thomas G (2003) Intrinsic susceptibility to radiation-induced apoptosis of human lymphocyte subpopulations. Int J Radiat Oncol Biol Phys 57:769–778Google Scholar
  89. Scholz M, Engel C, Loeffler M (2006) Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia. Br J Haematol 132:723–735CrossRefGoogle Scholar
  90. Schroen AT, Cress RD (2001) Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study. Ann Surg 234:41–51CrossRefGoogle Scholar
  91. Shankar AG, Pinkerton CR, Atra A, Ashley S, Lewis I, Spooner D, Cannon S, Grimer R, Cotterill SJ, Craft AW (1999) Local therapy and other factors influencing site of relapse in patients with localised Ewing’s sarcoma. United Kingdom children’s cancer study group (UKCCSG). Eur J Cancer 35:698–704CrossRefGoogle Scholar
  92. Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duehmke E, Georgii Engert A, Loeffler M, Diehl V, Mueller RP, Willich N, Fischer R, Hansmann ML, Stein H, Koch B, Schober T (2004) Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s lymphoma study group HD6 trial. Ann Oncol 15:76–82CrossRefGoogle Scholar
  93. Siegfried JM (2001) Women and lung cancer: does oestrogen play a role? Lancet Oncol 2:506–513CrossRefGoogle Scholar
  94. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D, Shepherd FA (2005) Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 23:50–56CrossRefGoogle Scholar
  95. Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O’Connell MJ, Loprinzi CL (2002) Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20:1491–1498CrossRefGoogle Scholar
  96. Sorensen KJ, Zetterberg LA, Nelson DO, Grawe J, Tucker JD (2000) The in vivo dose rate effect of chronic gamma radiation in mice: translocation and micronucleus analyzes. Mutat Res 457:125–136Google Scholar
  97. Soyuer S, Chang EL, Selek U, Shi W, Maor MH, DeMonte F (2004) Radiotherapy after surgery for benign cerebral meningioma. Radiother Oncol 71:5–90CrossRefGoogle Scholar
  98. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75:1–7CrossRefGoogle Scholar
  99. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P (2004) In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol 57:97–609CrossRefGoogle Scholar
  100. Teo P, Yu P, Lee WY, Leung SF, Kwan WH, Yu KH, Choi P, Johnson PJ (1996) Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys 36:91–304Google Scholar
  101. Tepper JE, O’Connell M, Niedzwiecki D, Hollis DR, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ (2002) Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114. J Clin Oncol 20:744–750CrossRefGoogle Scholar
  102. Thierens H, Vral A, Morthier R, Aousalah B, De Ridder L (2000) Cytogenetic monitoring of hospital workers occupationally exposed to ionizing radiation using the micronucleus centromere assay. Mutagenesis 15:245–249CrossRefGoogle Scholar
  103. Trott KR, Herrmann T, Kasper M (2004) Target cells in radiation pneumopathy. Int J Radiat Oncol Biol Phys 58:463–469Google Scholar
  104. Tsalic M, Bar-Sela G, Beny A, Visel B, Haim N (2003) Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo clinic regimen): a prospective study in colorectal cancer patients. Am J Clin Oncol 26:103–106CrossRefGoogle Scholar
  105. Visbal AL, Williams BA, Nichols FC 3rd, Marks RS, Jett JR, Aubry MC, Edell ES, Wampfler JA, Molina JR, Yang P (2004) Gender differences in non-small-cell lung cancer survival: an analysis of 4, 618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 8:09–15 discussion 215Google Scholar
  106. Wang LE, Bondy ML, de Andrade M, Strom SS, Wang X, Sigurdson A, Spitz MR, Wei Q (2000) Gender difference in smoking effect on chromosome sensitivity to gamma radiation in a healthy population. Radiat Res 154:20–27CrossRefGoogle Scholar
  107. Werner-Wasik M, Scott C, Cox JD, Sause WT, Byhardt RW, Asbell S, Russell A, Komaki R, Lee JS (2000) Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48:475–482Google Scholar
  108. Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K, Koeffler HP (2004) Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 10:2072–2081CrossRefGoogle Scholar
  109. Zalcberg J, Kerr D, Seymour L, Palmer M (1998) Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex international study group. Eur J Cancer 34:871–875CrossRefGoogle Scholar
  110. Zijno A, Marcon F, Leopardi P, Crebelli R (1996) Analysis of chromosome segregation in cytokinesis-blocked human lymphocytes: non-disjunction is the prevalent damage resulting from low dose exposure to spindle poisons. Mutagenesis 11:335–340CrossRefGoogle Scholar
  111. Zogopoulos G, Teskey L, Sung L, Dix D, Grant R, Greenberg ML, Weitzman S (2004) Ewing sarcoma: favourable results with combined modality therapy and conservative use of radiotherapy. Pediatr Blood Cancer 43:5–9CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Kerstin Borgmann
    • 1
  • Ekkehard Dikomey
    • 1
  • Cordula Petersen
    • 2
  • Petra Feyer
    • 3
  • Ulrike Hoeller
    • 3
  1. 1.Laboratory of Radiobiology Experimental Radiooncology, Clinic of Radiotherapy and RadiooncologyUniversity Medical Center Hamburg-EppendorfHamburgGermany
  2. 2.Practice for RadiotherapyHamburgGermany
  3. 3.Klinikum NeukoellnBerlinGermany

Personalised recommendations